Table 4.

PFS by Treatment: All Rigorously Staged Patients With Stage I Disease Receiving Watchful Waiting, R-Mono, R-Chemo, XRT, or CM:XRT

Outcome	XRT (n = 56)		Watchful Waiting(n = 35)		R-Mono (n = 25)		R-Chemo (n = 57)		CM:XRT (n = 26)
	HR	95% CI	HR	95% CI	HR	95% CI	HR	95% CI	HR	95% CI
PFS events
No.	18		9		6		9		1
%	32		26		24		16		4
PFS, months
Median	72		NR		NR		NR		NR
95% CI	50.5 to NR
Relative to XRT
Unadjusted			0.93	0.42 to 2.08	0.65	0.26 to 1.63	0.39	0.18 to 0.87	0.09	0.01 to 0.67
Adjusted*			1.02	0.45 to 2.34	0.56	0.21 to 1.48	0.36	0.16 to 0.82	0.11	0.01 to 0.83
Relative to watchful waiting
Unadjusted					0.69	0.25 to 1.95	0.42	0.17 to 1.06	0.10	0.01 to 0.76
Adjusted*					0.55	0.18 to 1.62	0.35	0.13 to 0.94	0.10	0.01 to 0.88
Relative to R-mono
Unadjusted							0.60	0.21 to 1.70	0.14	0.02 to 1.15
Adjusted*							0.65	0.23 to 1.84	0.19	0.02 to 1.67

NOTE. The median PFS follow-up for rigorously staged patients with stage I disease was 57 months.

Abbreviations: CM:XRT, combined modality with radiation therapy; HR, hazard ratio; NR, median PFS was not reached; PFS, progression-free survival; R-chemo, rituximab/chemotherapy; R-mono, rituximab monotherapy; XRT, radiation therapy.

^*Adjusted for grade, LDH, and B symptoms.